Optimizing insulin injection technique and its effect on blood glucose control  by Grassi, Giorgio et al.
Contents lists available at ScienceDirect
Journal of Clinical & Translational Endocrinology
journal homepage: www.elsevier .com/locate/ jcte
Journal of Clinical & Translational Endocrinology 1 (2014) 145e150Research PaperOptimizing insulin injection technique and its effect on blood glucose
controlq
Giorgio Grassi, MD a, Paola Scuntero, RN b, Rosalba Trepiccioni, RN c,
Francesca Marubbi, PhD d, Kenneth Strauss, MD e,*
a S.C.D.U. Endocrinologia, Diabetologia e Metabolismo, A.O. Citta’ Della Salute E Della Scienza, Torino, Italy
bC.P.S.E.I. Centro Uniﬁcato Diabetologia, A.O. Citta’ Della Salute E Della Scienza Torino, Italy
c S.C. Endocrinologia Diabetologia e Malattie del Metabolismo, Asl To2 e Ospedale Maria Vittoria, Italy
dBD Medical, Via delle Azalee 19, 20090 Buccinasco, MI, Italy
eBD, POB 13, Erembodegem-Dorp 86, B-9320 Erembodegem-Aalst, Belgiuma r t i c l e i n f o
Article history:
Received 24 May 2014
Received in revised form
10 July 2014
Accepted 10 July 2014
Keywords:
Insulin injection
Lipohypertrophy
Site rotation
Injection educationq This is an open access article under the CC
creativecommons.org/licenses/by-nc-nd/3.0/).
Conﬂict of interest: None declared.
Funding: No funding received.
* Corresponding author. Tel.: þ32 475 380 454; fax
E-mail address: kenneth_strauss@Europe.bd.com (
2214-6237  2014 The Authors. Published by Elsevier
http://dx.doi.org/10.1016/j.jcte.2014.07.006a b s t r a c t
Purpose: The purpose of the study is to assess whether proper Injection Technique (IT) is associated with
improved glucose control over a three month period.
Methods: Patients (N ¼ 346) with diabetes from 18 ambulatory centers throughout northern Italy who
had been injecting insulin  four years answered a questionnaire about their IT. The nurse then
examined the patient’s injection sites for the presence of lipohypertrophy (LH), followed by an indi-
vidualized training session in which sub-optimal IT practices highlighted in the questionnaire were
addressed. All patients were taught to rotate sites correctly to avoid LH and were begun on 4 mm pen
needles to avoid intramuscular (IM) injections. They were instructed not to reuse needles.
Results: Nearly 49% of patients were found to have LH at study entry. After three months, patients
had mean reductions in HbA1c of 0.58% (0.50%e0.66%, 95% CI), in fasting blood glucose of 14 mg/dL
(10.2e17.8 mg/dL, 95% CI) and in total daily insulin dose of 2.0 IU (1.4e2.5 IU, 95% CI) all with p < 0.05.
Follow-up questionnaires showed signiﬁcant numbers of patients recognized the importance of IT and
were performing their injections more correctly. The majority found the 4 mm needle convenient and
comfortable.
Conclusions: Targeted individualized training in IT, including the switch to a 4 mm needle, is associated
with improved glucose control, greater satisfaction with therapy, better and simpler injection practices
and possibly lower consumption of insulin after only a three month period.
 2014 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
Most physician visits with insulin-injecting patients involve
discussions about glucose control and dose adjustments, but very
little time is spent on improving Injection Technique (IT). However
IT may in certain cases be just as important to diabetes manage-
ment as the type of insulin or dosage used.
This study was the outgrowth of a survey performed in 21 hos-
pitals in northern Italy in 2011 by the ANIED Group e Associazione
Nazionale Infermieri in Endocrinologia e Diabetologia (National
Association of Nurses in Diabetology and Endocrinology; seeBY-NC-ND license (http://
: þ32 53 720 458.
K. Strauss).
Inc. Open access under CC BY-NC-ND liceAcknowledgments section) [1]. That study, termed the Swansdown
Survey and done in the same centers as our study, involved 472
injecting patients and consisted of training to improve their injecting
technique. Patients were using a variety of needle lengths (12.7 mm
[1.2%], 8 mm [37.7], 6 mm [35.4%], 5 mm [18.4%], 4 mm [7.6%], un-
known [5%]). No needle length changes were proscribed by the
study. Patients were followed up at 3 and 6 months for effects of the
training on their glucose control and injection technique knowledge.
No signiﬁcant changes were found in HbA1c or fasting glucose levels,
but understanding of injections was improved. The Survey had
initially revealed that the greatest educational needs were in older
patients who had been injecting insulin for over ten years and who
had outdated practices. By study conclusion a majority of patients
showed improved understanding of injecting devices (including
shorter, ﬁner-gauge needles), the care and maintenance of injection
sites, the means for avoiding complications such as lipohypertrophy
(LH) and the necessity for rotating injection sites. As a result of thisnse.
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tion in optimal IT as well as individualized and targeted attention to
speciﬁc needs as revealed by patient questionnaires and hands-on
nurse examinations.
Studies have been published in recent years supporting the
safety, efﬁcacy and patient preference for the 4mmpen needle (PN)
[2e9]. These needles have been shown to provide equivalent
glucose control compared to longer needles while reducing both
the risk of IM injections as well as injection pain. For these reasons
it was felt that the 4 mm PN played an integral role in optimizing IT
and should be the needle of choice for all injecting patients in the
participating centers. Since the switch to this needle was planned
anyway, we decided to study several glucose control and IT pa-
rameters at the same time. We evaluated the effects of an inte-
grated IT educational approach which included general and
targeted training, advice on rotation of sites and needle reuse as
well as a switch to the shortest PN (4 mm).
Methods
Patients with diabetes from 18 ambulatory centers throughout
the Piedmont region of northern Italy (Table 1) who had been
injecting insulin for at least four years were queried by their nurse/
educator using a questionnaire (Table 2) about their IT. The nurse
then examined the patient’s injection sites for the presence of ab-
normalities including LH. A general IT education session lasting
approximately 15 min was given using the BD Educational Starter
Kit (Becton Dickinson, Inc., Franklin Lakes, NJ, USA). The kit con-
tains site rotation grids, an educational injection technique leaﬂet
and a blood-glucose log-book. The ‘look and feel’ of LH was taught
using a BD ‘Lipobox’, which provided visual and tactile practice on
typical LH lesions. This general training was followed by an indi-
vidualized training session in which sub-optimal IT practices
highlighted in the patient’s questionnaire were addressed. All pa-
tients were taught how to rotate sites correctly to avoid LH and all
were begun on the BD Micro-Fine 4 mm 32G pen needle (Becton
Dickinson, Inc., Franklin Lakes, NJ, USA) to avoid intramuscular (IM)
injections. They were also instructed not to reuse the needles.
Furthermore each patient received an information card in which
ANIED underlines the importance that IT has in achieving optimal
glucose control.
The nurses involved in this study were trained at the time of
the Swansdown Survey [1] in 2011 on correct IT using theTable 1
Participating centers and subjects
Province City Center
AL Novi Ligure CAD Osp. San Giacomo
Acqui Terme CAD Osp. Civile Monsignor Galliano
Tortona CAD Osp. SS Antonio e Margherita
Alessandria CAD A.S.O. SS Antonio Biagio e Cesare
CN Cuneo CAD A.S.O. Santa Croce e Carle
Fossano CAD Osp. SS Trinita0
Fossano F.A.N.D.
TO Torino CAD A.S.O. C.T.O. (Città della Salute e d
Torino CAD Osp. Regina Margherita (Città del
Torino CAD Via Monginevro ASL To1
Torino CAD Osp. Maria Vittoria
Torino CAD S.G.A.S. (Città della Salute e della
Torino CAD A.S.O. Ordine Mauriziano Umbert
BI VCO VL Omegna CAD Osp. Madonna del Popolo
Verbania CAD Osp. Castelli
Domodossola CAD Osp. San Biagio
Vercelli CAD P.O. S. Andrea
Biella CAD Osp. Degli Infermi
Totalpublished New Injection Recommendations [10]. The question-
naire used by patients and nurses was reviewed point by point
and each nurse was certiﬁed on proper methodology for
administrating the questionnaire as well as for performing the
physical exam. Shortly before our study began in 2012, the same
nurses met for a 4-h roundtable in Turin, managed by the ANIED
scientiﬁc board, to review and discuss the Swansdown results
[1], and to create the ANIED Card. This card teaches patients
correct IT. At the same roundtable the nurses reviewed the new
trial protocol, with emphasis on inclusion and exclusion criteria.
All participating nurses were then trained on the ‘ANIED Card’
which would then be used to train all patients on correct IT
during the general education session. The entrance and exit
questionnaires were reviewed point-by-point with explanation
and discussion of every question. There were instructions on
minimizing drop-out and ensuring follow-up. Each nurse had to
demonstrate expertise in history taking, gathering of laboratory
data in an appropriate manner as well as in the use of a uniform
methodology for observing and palpating injection sites. Hands-
on certiﬁcation was required in the proper use of the Starter
Kit and Lipobox. Structured education techniques were taught
and certiﬁed including the correct explanation of injection
rotation, the use of a 4 mm needle and detailed LH
management.
Inclusion Criteria for patients included age >12 years, having
type 1 diabetes (T1D) or type 2 (T2D) and being on injection therapy
for at least four years. It was felt that subjects injecting for less than
four years might have already been exposed to the most up-dated
teaching in IT. By four years, however, subjects were felt to have
already established habits which might need corrective education
and training. Nevertheless, if subjects were still in their teens (13e
19 years old) the four-year requirement was waived. Subjects of all
body mass index (BMI) and using all marketed needle lengths were
accepted into the study.
Because of the time commitments needed to administer the
questionnaire and provide both general and individual training, it
was often not possible to include all patients seen on a daily basis in
any center. Hence nurses were instructed to admit to the study
either the ﬁrst one or two patients of the day who satisﬁed the
inclusion criteria or the ﬁrst and last patients of the day who
satisﬁed the inclusion criteria. If time permitted, all patients who
satisﬁed the inclusion criteria in a day were included. While not
strict randomization, this approach helped prevent selection bias.Total PTS PTS with HbA1c at exit
105 98
Arrigo
39 32
ella Scienza) 116 91
la Salute e della Scienza)
Scienza)
o I
86 38
346 259
Table 2
Key study questionsa
How many injections do you give per day?
What injection sites do you use?
When do you give your injections?
What needle length do you use?
Do you use the pinch-up technique?
If so, when do you release the pinch?
How long do you leave the needle in the skin after the injection?
Does the injection cause bleeding or bruising?
How often do you use the same needle?
At what angle do you insert the needle? 45 , 90 or other?
How would you describe the experience of injection in terms of pain?
bHow important was it for you to use a short needle?
bWhat did using a 4 mm  32 g needle feel like?
a This is a selection of questions; the full questionnaire is available on request.
b These questions were only posed at the end.
Table 3B
Parameters at study entry
N %
Females/Males 166/176 48.1/51.9
Visible lipohypertrophy 124 35.7
Visible lipoatrophy 18 5.2
Palpable lipohypertrophy 159 45.8
Total lipohypertrophya 169 48.7
5 mm needle used 111 33.3
6 mm needle used 139 41.7
8 mm needle used 79 23.7
12.7 mm needle used 4 1.2
Abdomen used primarily for injections 163 47.0
Thigh used primarily for injections 83 23.9
Buttocks used primarily for injections 14 4.0
Arm used primarily for injections 79 21.8
a Those with both visible and palpable lipohypertrophy are only counted once.
Table 4A
Clinical parameters at study entry and at three months
Clinical parameter n Mean D SD Minimum Maximum
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evaluate for LH and how to train patients on IT. Each patient was
taught the correct way to inject using a 4 mm PN and were told
they would be evaluated after the ﬁrst 3 months in order to assess
their IT, changes in clinical parameters, the state of their injection
sites and their psychological reaction to and clinical impact of the
4 mm PN (see ﬁnal questions in Table 2).
Every patient was informed that data from their questionnaire
would be maintained in strict conﬁdentiality, with only his/her
doctor and nurse having access to their identity. They were told
that it was not important to give the correct answer (‘this is not an
examination!’) and that they should not try to give the answer
they thought their nurse or doctor might want to know. It was
reinforced that to help them optimize their care it was extremely
important to give accurate, true answers. No patient was paid for
participating or otherwise rewarded. They were informed that the
reason for doing the study was to help them optimize their own
therapy, to uncover issues which individually-tailored training
could address and that the global information from the study
would help them and other patients by providing an improved
educational approach.
HbA1c values from the 18 centers were obtained from in-
struments which were calibrated every month and underwent an
optical control every time they were moved. The instruments were
qualiﬁed for use in the diagnosis of diabetes andwere shown to give
equivalent readings across centers.
Patients gave verbal consent to participate and the study was
conducted in accordance with Good Clinical Practice, the clinical
trials directives of the EU and the 1964 Declaration of Helsinki and
its six revisions. The study started in January, 2012 when the nurses
were trained. Patient recruitment began in February, 2012 and
lasted to April, 2012 and 3-month follow up lasted from May, 2012
to July, 2012.
SPSS software (IBMCorporation, ArmonkNY, USA, version19)was
used to analyze the data. Mean, median, standard deviation, mini-
mum,maximumand standard erroraround themeanweremeasured
for the entire population. Comparisons of parameters were per-
formed using c-square, ANOVA, log linear models and multivariate
analysis. The threshold for statistical signiﬁcance was a ¼ 0.05.Table 3A
Overall patient demographics
N Mean Std. deviation Minimum Maximum
Age (years) 346 55.5 18.6 11.0 85.0
Age at insulin
inception (years)
325 42.2 21.4 1.0 80.0
Years on insulin 332 13.0 9.8 0.5 50.0
Injections/Day 342 3.71 0.89 1.0 7.0Results
A total of 346 patients were included in the study. Demographic
data are given in Tables 3A and 3B and the key clinical parameter
changes in Tables 4A and 4B.
Age and gender parameters, years on insulin, total daily doses
(TDD) of insulin and injections/day were all in keeping with pre-
vious studies in patients with diabetes [2,4,11,12]. At study entry
patients were found to be using a variety of needle lengths, with a
majority on PN  6 mm long; none used the 4 mm PN. Most pa-
tients used the four conventional injection sites (abdomen, thighs,
upper arm and buttocks) although the buttock was used much less
frequently than the others. A number of patients were found to be
injecting in sites other than these four. Figure 1 illustrates some of
these unusual practices which were addressed during individual-
ized training.
By visual inspection at study entry nurses found LH in 35.7% of
patients and by palpation, in 45.8% (Figure 2). The overall LH per-
centage when visual and touch evaluations were combined was
48.7%. Those with both visible and palpable LH were only counted
once in determining the latter percentage.
After three months, patients had mean reductions in HbA1c of
0.58% (0.50%e0.66%, 95% CI), in fasting blood glucose of 14 mg/dL
(10.2e17.8 mg/dL, 95% CI) and in total daily insulin dose of 2.0 IU
(1.4e2.5 IU, 95% CI) with a p < 0.05 for all differences (Table 4A).
Body mass index (BMI) decreased slightly over the three months of
the study but this change was not statistically signiﬁcant. LH rates
were unchanged at three months. Follow-up HbA1c data were
available on only 259 of the 346 subjects (74.9%) included at
baseline (Table 1). However analysis of the demographic and clin-
ical data on the 259 was compared to that of the 346 and similar
results were obtained for HbA1c, fasting blood glucose and total
insulin doses.HbA1c at entry 346 8.49 2.86 5.2 14.0
HbA1c at 3 months 259 7.91 0.58* 1.30 5.1 14.1
FBG (mg/dL)at entry 249 186.7 49.9 90 410
FBG (mg/dL)at 3 months 182 172.5 14.2* 42.3 81 358
TDD (IU) insulin at entry 326 50.5 24.7 9 159
TDD (IU)
insulin at 3 months
256 48.5 2.0* 24.8 9 150
BMIa at entry 304 28.2 7.77 17.0 103.0
BMI at 3 months 235 27.7 0.5 8.20 16.5 102.0
*p < 0.05.
a BMI ¼ height (in meters)/(weight in kg)2.
Table 4B
Injection parameters at study entry and at three months
Practice parameter N % D in %
Use of pinch up at entry 121 34.9
Use of pinch up at 3 monthsa 31 8.9 26.0*
<5 s dwell time after injection at entryb 133 38.3
<5 s dwell time after injection at 3 months 21 6.1 32.2*
5e10 s dwell time after injection at entry 193 55.6
5e10 s dwell time after injection at 3 months 125 36.0 19.6*
>10 s dwell time after injection at entry 50 16.7
>10 s dwell time after injection at 3 months 162 46.7 þ30.0*
Use needle only once at entry 294 84.7
Use needle only once at 3 months 301 86.7 þ2.0
Consider injection technique VERY IMPORTANT at entry 139 40.1
Consider injection technique
VERY IMPORTANT at 3 months
224 64.6 þ24.5*
Consider injection technique IMPORTANT at entry 151 43.5
Consider injection technique IMPORTANT at 3 months 68 19.6 23.9*
Consider injection technique
SLIGHTLY IMPORTANT at entry
39 11.2
Consider injection technique
SLIGHTLY IMPORTANT at 3 months
9 2.6 8.6
Consider injection technique NOT IMPORTANT at entry 13 3.7
Consider injection technique
NOT IMPORTANT at 3 months
6 1.7 2.0
VERY HAPPY with current needle at entry 255 73.5
VERY HAPPY with the 4 mm needle at 3 months 314 88.9 þ15.4*
OK with current needle at entry 82 23.6
OK with the 4 mm needle at 3 months 31 8.9 14.7*
UNHAPPY with current needle at entry 5 1.4
UNHAPPY with the 4 mm needle at 3 months 3 0.9 0.5
*p < 0.05.
a Pinching up the skin is not necessary with a 4 mm pen needle for patients older
than 6 years (all subjects in this study).
b Best practice is a dwell time of >10 s, next best is 5e10 s and worst is <5 s.
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three months (Table 4B). Speciﬁcally, most patients had abandoned
the pinch-up technique when using the 4 mm PN. There was a
signiﬁcant shift in favor of longer ‘in-dwell’ times, with more pa-
tients leaving the needle under the skin for a full 10 s after
depressing the plunger. Proper IT was rated as important or very
important by signiﬁcantly higher percentages of patients than at
study initiation. And a majority of patients indicated high levels of
satisfactionwith the 4mmPN. Needle reusewas not common at the
start of the study (w15% of subjects) and did not change signiﬁ-
cantly by the end of the three-month period.
Discussion
This study investigated the effects of an integrated IT educa-
tional approach which included general and targeted training,
advice on rotation of sites and needle reuse as well as a switch toFigure 1. Injections into unconventional sites: Patient A, into the elbow regionthe shortest PN (4 mm). All patients underwent a multimodal
intervention (training, needle length, questionnaire), thus retro-
spectively it is impossible to determine with certainty which was
the causative component of the intervention. It is very possible that
the combination of all three interventions was effective. We found
that this approach can lead to improved glucose control, greater
satisfaction with therapy and lower daily consumption of insulin
over a relatively short period of time. These positive results could
contribute to better therapy adherence and, if sustained, improved
long-term clinical outcomes.
The glucose control improvements seen in our study differ from
results in the Swansdown Survey [1] conducted in the same centers
several months before. In the latter no improvements in control
were seen although a majority of patients exhibited better under-
standing of injection technique. This difference may be explained
by the nature of the intervention. In Swansdown there was a gen-
eral education session regarding injection technique given once to
patients, while in our study the same general education was given
but a questionnaire was also used to identify speciﬁc patient needs.
These were then addressed using a tailored individualized
approach. All patients were assessed for LH and moved to healthy
sites if they had LH and were injecting into it. And all patients were
switched to a 4 mm needle in order to facilitate wider site rotation
without increasing the risk of IM injections. It is this mosaic of in-
terventions which, we feel, made the difference, and which we now
recommend to others.
The percentage of our patients with LH (48.7%) was similar to
that found in three other published studies [11,13,14]. Other de-
mographic results were also similar suggesting that our patient
population is typical of others on a worldwide basis; hence we
believe our ﬁndings can be widely applied.
A series of clinical trials evaluating different needle lengths and
gauges [12,15,16] have shown advantages of shorter, ﬁner-gauge
needles over longer ones (principally in quality of life measures
such as reduced pain and patient preference), but such studies have
never shown an improvement in glucose control; all such studies
have been of a non-inferiority design. Several studies have also
shown a reduction in the frequency of IM injections when using
shorter needles [7,8,17,18] therefore it stood to reason that clinical
parameters such as improved HbA1c might eventually be found to
be associated with these needles. To our knowledge our study is the
ﬁrst to do so.
Traditionally the choice of needle length has been based on local
habits or economic factors, or, at best, on an assessment of a pa-
tient’s body habitus. However recent studies looking directly at the
anatomy of the skin and SC tissue using ultrasound [8,19,20] have
provided precise data on patients with diabetes and have made the
choice of needle length more evidence-based. The skin thickness
of adults [20] and children with diabetes [5] is approximately(see cluster of needle marks) and Patient B into the forearm (see bruises).
Figure 2. Examples of visible lipohypertrophy (A. Bilateral upper abdomen; B. Bilateral lower abdomen); see arrows.
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needle is more than long enough to pass through the skin and
enter the SC space.
However the distance from the skin surface to the muscle varies
widely both from one person to another and within the usual in-
jection sites in a single individual [8,14,19,20]. These results have
given pause to those who once advocated routinely using longer
needles (8 mm). In many normal to lean adults and in most
children there is a substantial risk of IM injections with such nee-
dles. Even in obese patients who inject into the limbs (arms or legs)
such risks are not trivial. Hence we have seen in recent years a shift
to shorter needles. This was the rationale of ANIED in shifting all
injecting patients in the Piedmont region of northern Italy over to
the 4 mm PN, in the context of an educational IT intervention.
The 4 mm PN has been tested in a number of clinical trials to
date [2e4,6,9] and has proven its safety and efﬁcacy in both adults
and children, as well as in persons spanning a range of BMIs,
including in the obese. Hirsch et al. [2], for example, showed similar
glycemic control (as measured by fructosamine values) during all
stages of a 3-week two-period crossover study that compared the
BD 32-gauge, 4-mm insulin PN with 31-gauge 5-mm and 31-gauge
8-mm needles [2]. In a follow-up randomized, controlled crossover
study with 3-month treatment periods using HbA1c to measure
control, the same results with the 4 mm PN were conﬁrmed in an
obese (BMI 30 kg/m2) diabetic population, many taking very large
insulin doses [21,22].
The latest consensus injection recommendations [10] state that
4 mm PN ‘may be used by any adult patient including obese ones
and do not generally require the lifting of a skin fold’ and that
children and adolescents ‘should use’ such needles. We found that
educational interventions regarding IT coupled with a switch to the
4 mm PN are associated with improved glucose control in a rela-
tively short period of time.
The weight of each of these interventions in the overall out-
comes was not evaluated. Limitations of our study include the lack
of a control group and the sequential nature (pre-post) of our an-
alyses; furthermore, we do not yet have long-term data. We did not
include a control group in this study because we felt obliged to give
the same best-practice advice to all our patients. In fact IT review
and a switch to a shorter needle is standard practice by the nurses
and doctors in the participating centers. Lack of a control prevents
absolute certainty that the 4 mm needle and IT training were the
exclusive causes of the clinical improvements we observed. Lack of
chronic follow-up data limits our knowledge as to how sustainable
these improvements might be.
Another important limitation is that we have follow-up HbA1c
data on only 259 of the 346 subjects (74.9%) included at baseline.
Nevertheless, analysis of the data on the 259 was compared to that
of the 346 and similar results were obtained, suggesting that results
from the former can be extrapolated to the latter. Hypoglycemiawas not assessed because of our inability to certify glucose values
when hypoglycemic symptoms appeared; not all patients were
using meters. Our ﬁndings however warrant further study in a
prospective, randomized controlled clinical investigation. Follow-
up for this trial was only planned for 3 months, but it has
continued and will be the subject of an additional analysis and
possible future paper.
The implications of our study are striking. Patients and pro-
fessionals do not have to wait for months and years to see im-
provements in the most important clinical parameters when
appropriate IT training and devices are provided. These improve-
ments can be expected early enough in the course of insulin therapy
to provide motivation for continuous improvement.Acknowledgments
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